Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02138097 · ClinicalTrials.gov registry record
Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns
A clinical trial, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- 615,067
- Enrollment target
NCT02138097 is a clinical trial that has completed, run by Boehringer Ingelheim. The registered enrollment target is 615,067 participants.
The verdict
NCT02138097 has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- 615,067 participants
- Enrollment target
Study Summary
This protocol is for a series of descriptive analyses conducted within a cohort of patients using linagliptin, other dipeptidyl peptidase-4 (DPP-4) inhibitors, and other oral and non-insulin injected hypoglycemic medications between May 2011 and July 2012. Understanding 1) the existing utilization patterns for linagliptin, sitagliptin, saxagliptin, and other oral and non-insulin injected hypoglycemic agents and (2) the differences in utilization patterns between these agents will help with the design, analysis and interpretation of comparative effectiveness and safety studies of linagliptin, other DPP-4 inhibitors, and other agents. The study will provide an overview of existing utilization patterns for linagliptin, other dipeptidyl peptidase-4 (DPP-4) inhibitors, other oral and non-insulin injected hypoglycemic agents, in order to detect potential selective prescribing patterns that might lead to channeling bias.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 615,067 participants |
| Start Date | 2014-05 |
| Est. Completion | 2014-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02138097
The ClinicalTrials.gov registry entry for NCT02138097 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 615,067 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02138097 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02138097 about?
NCT02138097 is a clinical study titled "Oral and Non-insulin Injected Hypoglycemic Therapy Utilization Patterns". This protocol is for a series of descriptive analyses conducted within a cohort of patients using linagliptin, other dipeptidyl peptidase-4 (DPP-4) inhibitors, and other oral and non-insulin injected hypoglycemic medications between May 2011 and July 2012. Understanding 1) the existing utilization ...
What is the current status of trial NCT02138097?
This trial is currently completed. The enrollment target is 615,067 participants. The study started on 2014-05. Estimated completion is 2014-08.
Who is sponsoring clinical trial NCT02138097?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.